In this article
IGF-DES is a shorter, cut-down version of a natural protein called insulin-like growth factor 1 (IGF-1). It belongs to the family of peptide hormones and growth factors. It is studied only in lab-based research and has not been approved by the FDA.
IGF-DES
What it is
IGF-DES, also written as Des(1-3)IGF-1, is a cut-down version of a natural protein called insulin-like growth factor 1 (IGF-1). Think of IGF-1 as a chain of small building blocks. IGF-DES is missing the first three building blocks at one end, known as the N-terminal amino acids (their names are glycine, proline, and glutamate). It belongs to the family of peptide hormones and growth factors. It occurs naturally in some tissues, and was first found in sources such as cow colostrum (the first milk a cow produces after giving birth) and human brain tissue in the early 1990s.
Research context and categorization
IGF-DES is grouped with other growth factors, alongside IGF-1 and similar molecules. Removing those three building blocks greatly reduces how well it sticks to certain proteins called IGF-binding proteins (IGFBPs). Think of IGFBPs as parking brakes that grab onto IGF-1 and slow it down. Because IGF-DES mostly skips past those brakes, it connects more freely to the IGF-1 receptor (the specific docking site on a cell). This is why researchers link it to increased potency (a stronger effect per unit). It also stays active for only a very short time once it is in solution.
Research Applications & Potency
In lab settings, researchers study IGF-DES to learn how it connects to growth-factor receptors, how it sends signals inside cells (called intracellular signaling pathways), how it affects protein production, and how it influences cells multiplying. It is also studied for cellular hypertrophy, meaning how cells grow larger, using cultured cell models (cells grown in laboratory dishes, not in a living body). Studies report that it is several times more potent than IGF-1 at stimulating cultured cells. Researchers believe this is because it binds less to the braking proteins (IGFBPs) described above.
These uses are investigational and limited to in vitro (cell and test-tube) and preclinical lab work. IGF-DES is not FDA-approved, and none of the research uses described here are confirmed or approved outcomes in humans or animals.
Status
- Regulatory status: Research-only, not FDA-approved. It is not approved for any medical use and is handled as a research chemical.
- Sport status: Prohibited under the WADA Prohibited List. IGF-1 and its analogs fall under class S2, Peptide Hormones, Growth Factors, Related Substances and Mimetics, which is prohibited at all times, both in and out of competition.
Reconstitution notes (general)
Concentration tells you how much peptide is dissolved in a set amount of liquid. You find it by dividing the milligrams of peptide in the vial by the millilitres of solvent added. For example, a 1 mg vial dissolved in 1 mL of solvent gives a concentration of 1 mg/mL. The same vial dissolved in 2 mL gives 0.5 mg/mL.
To check a target concentration against a given vial size and solvent volume, use the calculator at peptide calculator. Add solvent slowly down the inner wall of the vial rather than directly onto the powder, and let it dissolve without shaking.
Dilution and handling notes (compound-specific)
Key point: IGF-1 analogs like IGF-DES must be reconstituted (dissolved back into liquid) in a mildly acidic solvent rather than plain bacteriostatic water, to stop the peptide from clumping together and to ensure it dissolves properly.
Choosing the Right Solvent
IGF-DES comes as a lyophilized (freeze-dried) powder that must be reconstituted, meaning dissolved back into a liquid, before lab use. Unlike many research peptides, IGF-1 analogs such as IGF-DES are generally reconstituted in a mildly acidic solvent rather than plain bacteriostatic water.
Common choices include dilute acetic acid (for example around 0.6%) or dilute hydrochloric acid (for example about 10 mM). The acidic environment helps the peptide dissolve by putting a small charge on parts of its surface. Plain bacteriostatic water tends to leave this type of peptide poorly dissolved and can cause it to clump together, turn cloudy, or settle as a deposit at the bottom of the vial.
Reconstitution & Mixing Protocol
A working concentration of roughly 1 mg per 1 mL is often chosen because it is easy to measure and keeps the volume of acidic solvent small. If a protocol calls for a neutral buffer (a solution that is neither acidic nor basic), the usual approach is to dissolve the powder first in the acidic solvent and then slowly dilute it into the buffer. Prepare it fresh and handle it gently, since shaking and foaming can cause the peptide to clump.
Add solvent slowly and mix by gently swirling or rolling the vial between your palms rather than shaking it. Hard shaking puts stress on the peptide and can damage it. Dissolution may take about 30 seconds up to a few minutes depending on concentration. Let the solution clear fully before using it in the lab.
Handling and storage
Store the reconstituted solution in a refrigerator at 2 to 8 C and keep it away from direct light. Wipe the vial stopper with an alcohol swab before each withdrawal, and write the mix date on the vial label.
A refrigerated working window of roughly 4 weeks is commonly cited for reconstituted peptide solutions. Because the acidic reconstitution solvent does not contain the preservative (benzyl alcohol) found in bacteriostatic water, some lab workers divide the solution into small portions (aliquots) and freeze them for longer-term storage. Discard the solution if it turns cloudy or discolored, or if you see visible particles or floating matter.
Related reading
Tools and supplies
- peptide calculator
- Bacteriostatic Water 30 ml
- Gansulin Metal Reusable Pen
- 3 ml Glass Cartridges (10-pack)
- Complete Starter Kit
Reminder: research and educational reference only. Preppin Peppers sells hardware and materials, not peptides. Not medical, dosing, or health advice, not evaluated by the FDA, and not intended for human or animal use.
Frequently asked questions
What is IGF-DES and how does it differ from IGF-1?
IGF-DES, or Des(1-3)IGF-1, is a naturally occurring truncated form of IGF-1 lacking the first three N-terminal amino acids (glycine, proline, glutamate), first identified in bovine colostrum and human brain tissue in the early 1990s.
Why does IGF-DES show greater potency than IGF-1 in cultured cell research?
Removing the three N-terminal residues sharply reduces binding to IGF-binding proteins (IGFBPs), which normally sequester IGF-1. IGF-DES therefore engages the IGF-1 receptor more freely, producing a stronger signal per unit in vitro.
How is reconstitution concentration calculated for an IGF-DES research vial?
Divide the vial's peptide mass in milligrams by the solvent volume added in millilitres. Example: 1 mg dissolved in 2 mL yields 0.5 mg/mL. Add solvent slowly down the inner vial wall and allow dissolution without shaking.
What the research community gets wrong about IGF-DES
- The "DES" does not mean designer or synthetic. It is short for des(1-3), meaning the first three amino acids at one end have been removed. The molecule occurs naturally in tissues like bovine colostrum, so treating it as a wholly man-made construct misreads what is in the vial.
- "Several times more potent" is an assay result, not a fixed property. The higher potency numbers reported in the literature come from cultured cell work where reduced IGF-binding-protein (IGFBP) binding leaves more peptide free to reach the receptor. Change the IGFBP levels in the assay and the size of that difference changes too, so a single multiplier does not carry across every experiment.
- Reduced IGFBP binding is not zero binding. Studies describe weaker, not absent, affinity (for example, roughly an order of magnitude lower for IGFBP-3). Writing protocols as if the peptide ignores binding proteins entirely overstates what was measured.
- Plain bacteriostatic water is often assumed to be fine, and it usually is not for this analog. A mildly acidic solvent (dilute acetic acid or dilute HCl) is typically needed to keep it dissolved. Cloudiness or a deposit at the bottom of the vial is aggregation, not a sign the material is "working."
- Freeze-dried stability is not solution stability. The dry powder is stable, but once reconstituted this peptide stays active for only a short time and is sensitive to shaking and foaming. Handling the mixed solution by the same casual rules used for the sealed powder is a common mistake at the bench.
From our bench: If you have reconstituted an IGF-DES research vial, tell us what the solvent choice actually did. Compare a portion dissolved in a dilute acidic solvent against a portion in plain bacteriostatic water, and note what you observed: how long each took to clear, whether either turned cloudy or left a deposit, and the temperature and vial size you used. Share your real numbers and observations (no guesses), and we will add measured bench notes to this page.
Sources
- Bacteriostatic Water for Injection, USP , FDA/DailyMed label (0.9% benzyl alcohol)
- Duerkop et al., Biotechnol J 2018 , Impact of Cavitation, High Shear Stress and Air/Liquid Interfaces on Protein Aggregation
- Sigma-Aldrich (Merck) , Handling and Storage Guidelines for Peptides and Proteins
- Simes, Wallace & Walton (1991), J Endocrinol , des(1-3)IGF-I is more potent than IGF-I on GH/IGFBP secretion from cultured rat pituitary cells, due to reduced IGFBP binding
- Ricort & Binoux (2001), Endocrinology , des(1-3)IGF-I described as an IGF-I analog with intact type 1 IGF receptor affinity but weak or virtually no affinity for IGFBPs
✔ Reviewed by Bryan Le, PharmD, RPh
Bryan is a licensed pharmacist (Doctor of Pharmacy, Registered Pharmacist). Reconstituting lyophilized preparations is core pharmacy practice, so he reviews The Lab’s content for technical accuracy and to keep it within a research-and-education scope, with no medical or dosing advice. View profile on LinkedIn.
